Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …

Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …

Background Blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) are
important risk factors for cardiovascular (CV) diseases. Although treating these factors …

Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

Background Hypertension and hypercholesterolemia are important risk factors for
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …

The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …